Redhill Biopharma Ltd. (NASDAQ:RDHL) Stock Short Interest Declines 39.2%

by · The Cerbat Gem

Redhill Biopharma Ltd. (NASDAQ:RDHL – Get Free Report) was the recipient of a large decline in short interest in October. As of October 15th, there was short interest totaling 128,328 shares, a decline of 39.2% from the September 30th total of 211,200 shares. Currently, 1.5% of the shares of the stock are short sold. Based on an average daily volume of 1,568,822 shares, the short-interest ratio is currently 0.1 days.

Redhill Biopharma Stock Performance

NASDAQ RDHL opened at $0.39 on Friday. The company has a 50-day simple moving average of $0.56 and a two-hundred day simple moving average of $0.81. Redhill Biopharma has a 12-month low of $0.38 and a 12-month high of $1.60.

Analyst Ratings Changes

Separately, Weiss Ratings cut Redhill Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, October 6th. One equities research analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, Redhill Biopharma presently has an average rating of “Sell”.

Read Our Latest Stock Report on Redhill Biopharma

Redhill Biopharma Company Profile

(Get Free Report)

RedHill Biopharma Ltd. was a specialty biopharmaceutical company focused on developing and commercializing therapies for gastrointestinal diseases and infectious diseases. The company was founded in Israel and later operated as a publicly traded company in the United States under the ticker symbol RDHL.

RedHill’s principal commercial product was Talicia, an oral combination of omeprazole, amoxicillin and rifabutin approved by the U.S. Food and Drug Administration for the treatment of Helicobacter pylori infection in adults.

See Also